Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines

HUI-YAN LUO1*, WEI WEI2*, YAN-XIA SHI1, XIAO-QIN CHEN1, YU-HONG LI1, FENG WANG1, MIAO-ZHEN QIU1, FANG-HUA LI1, SHU-LI YAN3, MU-SHENG ZENG4, PENG HUANG5 and RUI-HUA XU1

1State Key Laboratory of Oncology in Southern China and Department of Medical Oncology; 2State Key Laboratory of Oncology in Southern China and Department of Hepatobiliary Oncology; 3State Key Laboratory of Oncology in Southern China and Department of Laboratory; 4State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-Sen University Cancer Center, Guangzhou, P.R. China; 5Department of Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Received January 18, 2010; Accepted March 12, 2010

DOI: 10.3892/or_00000819

Abstract. Hypoxia is recognized as an important factor contributing to cancer development and drug resistance. Cetuximab, a chimeric monoclonal antibody to EGFR, is known to inhibit HIF-1α expression levels and to enhance the cytotoxicity of chemotherapeutic agents. We demonstrated that hypoxia induced drug resistance in gastric cancer cells. Cetuximab enhanced oxaliplatin-induced cytotoxicity and apoptosis in normoxia and caused a reversal of drug resistance in hypoxia. Normoxic and hypoxic gastric cancer cells were treated with cetuximab, oxaliplatin or the combination and assessed for cell growth, proliferation, and apoptosis. Combination treatment resulted in a marked inhibition of HIF-1α expression levels in hypoxic cells and caused a significant reduction in the expression of activated phosphorylated AKT, ERK1/2, p-BAD and VEGF in both normoxia and hypoxia with greater levels of inhibition in hypoxia. In summary, cetuximab inhibits HIF-1α expression via the MAPK/ERK and PI3K/AKT signaling pathways and functions to overcome drug resistance induced by hypoxia. Cetuximab-oxaliplatin combination therapy may therefore emerge as an attractive treatment strategy for advanced gastric cancer.

Introduction

Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death in the world (1) with the highest incidence reported in Japan, Korea and China (2). The only potentially curative treatment for local gastric cancer is surgery. However, most cases of gastric cancer present at an advanced stage where the only possible management of the disease is via chemotherapy. The rapid development of new chemotherapeutic agents have done little to improve the prognosis of advanced and recurrent gastric cancer, with response rates ranging from 20 to 50% and the overall 5-year survival rates range from 5 to 15% (3). It is evident that new treatment options are urgently needed.

Hypoxia has been recognized as a common environmental stress contributing to the development of various malignancies. Hypoxia-inducible factor-1 (HIF-1) is the main regulatory protein in the cellular response to decreased oxygen levels (4,5). HIF-1 is a heterodimeric transcription factor (consisting of α and β subunits) that regulates the expression of genes involved in angiogenesis, cell proliferation and metabolism and drug sensitivity (6-8). The inducible α subunit is up-regulated in hypoxia and plays an integral role in the body’s response to hypoxia by increasing vascularization in hypoxic areas and promoting homeostasis. The β subunit is constitutively expressed (9). In normoxia, HIF-1α is hydroxylated by prolyl hydroxylase 2 (PHD2) and ubiquitinated by the von Hippel Lindau protein (VHL) thereby being targeted to the proteosomes for degradation. However, prolyl hydroxylation is inhibited in a hypoxic microenvironment, resulting in stabilization of the HIF-1α subunit which then translocates to the nucleus. HIF-1α subsequently dimerizes with the β subunit and transcriptionally activates a number of genes by binding to hypoxia-responsive elements (HREs) in their promoters (10-13). HIF-1α expression correlates with a poor...
prognosis and an inefficient response to treatment in a number of cancers including gastric cancer (14,15).

HIF-1α is also regulated by several non-oxygen-dependent mechanisms such as the activation of different oncogenes and the inactivation of tumor suppressor genes such as PAS, MYC, PTEN and VHL (11,16). Cytokines, epidermal growth factor (EGF) and insulin-like growth factor (IGF) are also known to play a role in the synthesis and functioning of HIF-1α via the activation of phosphatidylinositol 3-kinase (PI3-K)/AKT or mitogen-activated protein kinase (MAPK) pathways (17-19). The activation of PI3-K/AKT resulted in elevated HIF-1α protein levels while activation of the MAPK pathway resulted in increased transactivation by HIF-1α.

The epidermal growth factor receptor (EGFR), a member of the ErbB receptor family, is often overexpressed in a variety of human tumors with epithelial origin, including breast, gastric, colorectal, and non-small cell lung cancer (20). EGFR, a 170-kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity, consists of an extracellular ligand binding domain, a transmembrane region, and an intracellular tyrosine protein kinase domain (21). Overexpression of EGFR was associated with resistance to cytotoxic drugs and poor prognosis in cancer patients. The two major downstream signaling pathways of EGFR are 1) the Ras-Raf-MAPK pathway, which contributes to cell proliferation, survival, and transformation, and 2) the phosphatidylinositol 3-kinase (PI3-K) and the downstream protein-serine/threonine kinase AKT. Activation of AKT triggers a cascade of responses from cell growth and proliferation to survival and motility (22). These two signaling pathways lead to elevated HIF-1α levels (18,19).

Two recent strategies to target EGFR are 1) monoclonal antibodies directed at the ligand-binding extracellular domain which block ligand binding and receptor activation; and 2) small molecule tyrosine kinase inhibitors that compete with ATP for binding to the tyrosine kinase domain of the receptor (8,23). Cetuximab (C225, Erbitux) is a chimeric monoclonal antibody directed to the extracellular domain of EGFR. Numerous studies have shown that cetuximab inhibited the production of vascular endothelial growth factor (VEGF) in vitro and in vivo by inhibiting HIF-1α expression levels (24-28).

Oxaliplatin, a third generation platinum analog which has been extensively used to treat colorectal cancer, works by generating bulky platinum-DNA adducts that are poorly recognized by the mismatch repair system (29). A major drawback to using oxaliplatin-based therapy is the development of drug resistance similar to other platinum-based therapies. Cetuximab was shown to enhance the cytotoxicity of chemotherapeutic agents such as oxaliplatin, doxorubicin, paclitaxel, cisplatin, and topotecan on tumor xenografts derived from a variety of human cancer cells (30,31). In colorectal cancer, cetuximab potentiated DNA damage caused by oxaliplatin and combination treatment resulted in an enhanced anti-tumor effect (29).

Based on the above findings, we investigated the effect of cetuximab-oxaliplatin combination treatment on drug resistance and apoptosis in hypoxic gastric cancer cell lines and interrogated the molecular mechanisms of cetuximab-mediated inhibition of the EGFR signaling pathway leading to inhibition of HIF-1α levels and enhanced apoptosis. We demonstrated a significant downregulation in the levels of HIF-1α, pERK1/2, pAKT and pBAD (important survival signals) in oxaliplatin-cetuximab-treated gastric cancer cells, especially under hypoxic conditions. Cetuximab, which enhances the chemotherapeutic potential of oxaliplatin, thus emerges as an attractive new candidate in the treatment of gastric cancer and functions to circumvent drug resistance and increase apoptosis in these cells.

Materials and methods

Chemicals and reagents. Monoclonal antibody to EGFR (cetuximab C225) (2 mg/ml) was purchased from Merck (Darmstadt, Germany). Oxaliplatin (5 mg/ml) was purchased from Sanofi Synthelabo (Gentilly, France). Mouse monoclonal phospho-ERK1/2 antibody (Thr202/Tyr204), rabbit polyclonal ERK1/2 antibody, rabbit polyclonal phosphor-AKT antibody (Ser473), and rabbit polyclonal AKT antibody were all from Cell Signaling Technology Inc. (Beverly, MA, USA). Mouse monoclonal BAX antibody, rabbit polyclonal BAD antibody and rabbit polyclonal phospho-BAD (Ser112) antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibody against human HIF-1α was from BD Biosciences (San Jose, CA, USA).

Cell culture. Human gastric cell lines MGS-803 and SGC-7901 (kindly provided by the State Key Laboratory of Oncology in southern China and Department of Laboratory, China) were routinely cultured in RPMI-1640 medium (Invitrogen, CA, USA) supplemented with 10% new born calf serum (Invitrogen), 100 U/ml of penicillin and 100 μg/ml streptomycin (ICN, Irvine, UK) at 37°C in humidified air with 5% CO2. Hypoxia was achieved by incubating cells in a sealed modular incubator chamber (Billups-Rothenberg, Del Mar, CA) flushed with 1% O2, 4% CO2 and 95% N2.

Assays of cell growth and cytotoxicity. Cell growth inhibition was determined by directly counting the cells 24, 48 and 72 h after they were treated with cetuximab alone, oxaliplatin alone, or the combination. For combination treatment, cells were treated with cetuximab for 12 h prior to the addition of oxaliplatin. We found no significant difference between this regimen and simultaneous treatment with both drugs. Cell cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assay. Briefly, cells were seeded onto 96-well plates at a density of 4000 cells per well, incubated for 12 h to ensure attachment and then treated with cetuximab (0.25-100 μg/ml) and/or oxaliplatin (0.5-200 μM). After 72 h of treatment, the cells were treated with 5 mg/ml (20 μl/well) of MTT reagent and incubated for 4 h. The supernatant was removed and cell pellets were dissolved in 200 μl DMSO. Absorbance was determined using a MultiSkan plate reader (LabSystems, Helsinki, Finland) at a wavelength of 540 nm.

Apoptosis assays. Apoptosis was quantified by flow cytometry using the Annexin V-FITC and propidium iodide (PI) Apoptosis kit (Keygen Biotech, Nanjing, China) as follows: Cells that were treated with the different combinations of
cetuximab and oxaliplatin were collected, washed with cold PBS, and then suspended in Annexin-V-binding buffer solution. The cells were stained with Annexin V-FITC for 15 min at room temperature and then stained with PI. The samples were analyzed using a FACSCalibur flow cytometer equipped with Cell Quest-Pro software (Becton-Dickinson, San Jose, CA, USA). Each experiment was performed thrice with consistent results.

**Drug interaction analysis**

**Combination index (CI) calculations.** Cells were treated with oxaliplatin and cetuximab as described above. The cytotoxic effects obtained with oxaliplatin and cetuximab combinations were analyzed as described (32). Briefly, we determined the median inhibitory concentration (IC$_{50}$) for each drug in a fixed-ratio combination of the two drugs. For two drugs acting by mechanisms that are not mutually exclusive, the CI (combination index value) was calculated using the following formula: $CI = D_1/(IC_{50,1}) + D_2/(IC_{50,2}) + (D_1D_2)/(IC_{50,1} IC_{50,2})$. $D_1$ and $D_2$ are calculated from the IC$_{50}$ for the combination and the ratio (P/Q) of the two drugs as follows: $D_1 = (IC_{50})$ comb x P/(P+Q) and $D_2 = (IC_{50})$ comb x Q/(P+Q). The third (interaction) term is absent when the drug actions are mutually exclusive. For each drug combination in our study we used the Calcsyn software (Biosoft, Ferguson, MO) to calculate the CI for 4 concentrations (2:1 ratio) of the two drugs and averaged the CIs. A CI of 1 indicates additive effects, whereas a CI <1 indicates synergy.

**Immunoblotting.** In order to assess the expression of HIF-1α, ERK, phosphorylated ERK1/2, AKT and phosphorylated AKT proteins, cells were solubilized in lysis buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1% bromophenol blue, 2.5% β-mercaptoethanol). Total protein concentration of whole cell lysates was determined using BioRad BCA method (Pierce, Rockford, IL, USA). Equal amounts of protein were electrophoresed on 7.5-10% sodium dodecyl sulfate (SDS)-polyacrylamide gels and electroblotted onto nitrocellulose membranes (Hybond ECL, Amersham Pharmacia). After blocking with Tris-buffered saline (TBS)/5% skim milk or 5% BSA, the membranes were incubated overnight at 4°C with mouse monoclonal antibodies against human HIF-1α, BAX, or phosphorylated ERK1/2 or rabbit antibodies against total ERK, AKT, BAD, phosphorylated ERK1/2, AKT (Ser473) and BAD (Ser112). The membranes were washed, incubated with a horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (1:5000) or goat anti-rabbit (1:2000) (Cell Signaling Technology Inc.) for 1 h at room temperature, and visualized using enhanced chemiluminescence (ECL). Equal loading was verified by immunoblotting with a GAPDH antibody (Santa Cruz Biotechnology).

**ELISA assay for VEGF.** VEGF protein levels in the conditioned media were assayed using the Quantikine/Human VEGF ELISA kit (R&D Systems Inc., Minneapolis, MN) according to the manufacturer’s protocol. Briefly, cells were seeded onto 12-well plates at a density of 2x10^5 per well and incubated 12 h to ensure attachment. The cells were treated with cetuximab (50 μg/ml), oxaliplatin (100 μM, 200 μM) or a combination of the two drugs for 24 or 48 h as described above. The supernatants were collected and cells were counted in each well. The concentration of VEGF in the supernatant (100 μl) was determined and normalized by the cell numbers. A serial dilution of human recombinant VEGF was included in each assay to obtain a standard curve.

**Results**

**Cetuximab-oxaliplatin combination treatment inhibited cell growth in hypoxic gastric cancer cells.** We evaluated the effect of cetuximab alone, oxaliplatin alone and combination treatment on growth of gastric cancer cell lines. Normoxic and hypoxic MGC803 and SGC7901 gastric cancer cells were treated with cetuximab (50 μg/ml), oxaliplatin (100 μM), or the combination and the number of cells were counted directly. We showed that hypoxia caused a mild inhibition of cell growth (Fig. 1). Treatment of these cells with oxaliplatin alone had a more potent inhibitory effect on normoxic cells than on hypoxic cells. Cetuximab, by itself, did not inhibit cell growth. However, oxaliplatin-cetuximab combination treatment resulted in a more efficient inhibition of cell growth than either agent used alone. This effect was more potent in hypoxic cells than in normoxic cells.

Additionally, we used the MTT assay to evaluate the cytotoxic activity of cetuximab and oxaliplatin administrated alone or in combination on normoxic and hypoxic gastric cancer cell lines. Cetuximab alone was neither cytotoxic nor cytostatic even at 1000 μg/ml (data not shown). Oxaliplatin had an IC$_{50}$ of 5.76 μM in normoxic MGC803 cells and 4.98 μM in normoxic SGC7901 cells. However, the IC$_{50}$ of oxaliplatin decreased by 44.4% in MGC803 cells and 38.2% in SGC7901 cells (Table I) when combined with cetuximab. Oxaliplatin had an IC$_{50}$ of 20.55 μM in hypoxic MGC803 cells and 10.79 μM in hypoxic SGC7901 cells. However, the IC$_{50}$ of oxaliplatin decreased by 61.7% in MGC803 cells and 64.7% in SGC7901 cells (Table I) when combined with cetuximab. We tested the combination of cetuximab and...
irinotecan in normoxic and hypoxic gastric cancer cells and found similar results (data not shown).

These data showed that a) hypoxic gastric cancer cells were more resistant to the drug than normoxic cells, b) that cetuximab enhanced the cytotoxic effect of oxaliplatin in normoxia and hypoxia and c) that cetuximab enhanced the cytotoxic effect of oxaliplatin more efficiently in hypoxic cells than in normoxic cells (Table I).

**Oxaliplatin and cetuximab act synergistically on gastric cancer cells.** In order to quantitatively define the interaction between cetuximab and oxaliplatin on normoxic and hypoxic gastric cancer cells, we used a media-effect analysis program (32) to calculate the drug combination index (CI). The method uses mass action characteristics in order to quantitate the effect of multiple drugs in a system. CI is obtained by determining the fraction of cells affected and the concentration of drug required to produce a 50% effect. An additive effect would produce a CI value of 1, whereas synergistic and antagonistic effects would produce CI values of <1 and >1, respectively.

Gastric cancer cells were treated with various concentrations of oxaliplatin and cetuximab in a fixed ratio (2:1). The fraction-effect versus CI plots curves are displayed in Fig. 2. All the CI values were <1, demonstrating that the effects of the two drugs are synergistic. Furthermore, the CI values of treated hypoxic cells were lower than those of treated normoxic cells indicating that oxaliplatin and cetuximab exhibited more efficient synergy in hypoxia (Table II).

Hypoxic gastric cancer cells treated with cetuximab-oxaliplatin combination exhibited higher levels of apoptosis than cells treated with single agents. We investigated the effect of oxaliplatin-cetuximab combination treatment on the induction of programmed cell death in two different gastric cancer cell lines.
lines. MGC803 and SGC7901 cells were treated with oxaliplatin (100 μM, 200 μM), cetuximab (50 μg/ml), or the combination under normoxic or hypoxic conditions. Cetuximab treatment alone did not induce apoptosis in gastric cancer cell lines under either normoxic or hypoxic conditions. Oxaliplatin induced apoptosis in a dose- and time-dependent manner in both normoxic and hypoxic cells.

We demonstrated that hypoxia protected gastric cancer cells from oxaliplatin-induced apoptosis. Treatment of normoxic MGC803 cells with 100 μM oxaliplatin resulted in 28 and 53% apoptosis at 24 and 48 h respectively, while cetuximab (50 μg/ml) and oxaliplatin (100 μM) combination treatment resulted in 35 and 61% apoptosis at 24 and 48 h, respectively (Fig. 3a). Hypoxic MGC803 cells treated with 100 μM oxaliplatin exhibited 14 and 32% apoptosis at 24 and 48 h respectively, while cetuximab (50 μg/ml) and oxaliplatin (100 μM) combination therapy resulted in 34 and 54%

Table II. Synergistic activity of oxaliplatin and cetuximab in human gastric cancer cells.

<table>
<thead>
<tr>
<th>Cell</th>
<th>Oxaliplatin (μM)</th>
<th>Cetuximab (μg/ml)</th>
<th>Combination index Normoxia</th>
<th>Hypoxia</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGC 803</td>
<td>5</td>
<td>2.5</td>
<td>0.722</td>
<td>0.672</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>5</td>
<td>0.695</td>
<td>0.592</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>25</td>
<td>0.789</td>
<td>0.605</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>50</td>
<td>0.615</td>
<td>0.447</td>
</tr>
<tr>
<td>SGC 7901</td>
<td>5</td>
<td>2.5</td>
<td>0.881</td>
<td>0.605</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>5.0</td>
<td>0.837</td>
<td>0.673</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>25</td>
<td>0.705</td>
<td>0.540</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>50</td>
<td>0.522</td>
<td>0.362</td>
</tr>
</tbody>
</table>

The combination index (CI) values of oxaliplatin and cetuximab in hypoxic or normoxic MGC803 and SGC7901 cells were calculated using the Median Dose-Effect program by Chou and Hayball as described in Materials and methods. CI values <1 indicate synergy.
Figure 3. a-c. Synergistic effect of cetuximab and oxaliplatin on induction of apoptosis in human gastric cancer cells.
apoptosis at 24 and 48 h, respectively (Fig. 3b). We also showed that combination therapy enhanced oxaliplatin-induced apoptosis in normoxic and hypoxic SGC7901 cell lines (Fig. 3c and d). In summary, we showed that cetuximab-oxaliplatin combination treatment resulted in a higher percentage of apoptosis in hypoxic cells when compared with oxaliplatin treatment alone.

Effect of cetuximab and oxaliplatin on HIF-1α levels. In order to investigate the mechanism of cetuximab-mediated enhancement of apoptosis in oxaliplatin-treated hypoxic cells, we looked at the effect of cetuximab on the expression of HIF-1α. Gastric cancer cells were treated with cetuximab alone, oxaliplatin alone or the combination and HIF-1α expression was examined by immunoblotting. As expected, we found increased levels of HIF-1α expression in hypoxic cells (Fig. 4a) when compared with normoxic cells. Treatment of hypoxic cells with either cetuximab or oxaliplatin alone caused a moderate reduction in the expression levels of HIF-1α, but combination treatment caused an efficient inhibition of HIF-1α expression in these cells.

Effect of cetuximab and oxaliplatin on EGFR signaling pathways. PI3-K/AKT/BAD and ERK/MAPK have been reported to be the two major pathways that interact with HIF-1α (17-19) and are also the major intracellular downstream signaling pathways that are directly and indirectly activated in response to ligand-dependent EGFR activation. We therefore assessed the role of cetuximab and oxaliplatin on AKT and ERK1/2 phosphorylation in MGC803 cells. We demonstrated a slight reduction in the levels of phosphorylated AKT and phosphorylated ERK1/2 in normoxic and hypoxic cells treated with cetuximab. Treatment of these cells with oxaliplatin alone did not affect the phosphorylation of AKT and ERK1/2. Interestingly, oxaliplatin-cetuximab combination treatment resulted in efficient inhibition of p-AKT levels in both normoxic and hypoxic cells and of p-ERK1/2 levels in hypoxic cells (Fig. 4b and c). We found no change in the levels of total AKT and ERK1/2 in cetuximab-treated cells suggesting that cetuximab did not inhibit ERK1/2 and AKT synthesis.

The Bcl-2 family member BAD is an important pro-apoptotic downstream target of EGFR in mammary cells (33,34). Since EGF-induced phosphorylation of BAD is known to occur via the MAPK and PI3-K pathway (35), we evaluated the role of cetuximab and oxaliplatin on phosphorylation of BAD in normoxic and hypoxic cells. We showed that cetuximab treatment caused a decrease in phospho-BAD levels in hypoxic cells, while the decrease was not as marked in normoxic cells (Fig. 4c). These data suggest that EGF-induced phosphorylation of BAD occurs mainly through the MAPK and PI3-K pathways in these cells and agree with previous work showing the effect of small molecule inhibitors of EGFR on p-BAD (34). Treatment with oxaliplatin alone did not affect phospho-BAD levels in either normoxic or hypoxic cells. However, cetuximab-oxaliplatin combination therapy resulted in significant inhibition of phospho-BAD levels in hypoxic cells, which was consistent with the synergistic effect of these two compounds. No changes were observed in the total expression levels of BAD and BAX proteins. From these data, we conclude that cetuximab-oxaliplatin combination treatment causes 1) inhibition of MAPK and PI3-K/AKT signaling downstream of EGFR 2) inhibition of HIF-1α expression and ultimately 3) increased apoptosis in these cells.

Inhibition of hypoxia-induced expression of VEGF by cetuximab. VEGF, which is a downstream target of HIF-1α,
plays an important role in tumorigenesis, tumor invasion, metastasis and drug-resistance induced by hypoxia (6-8). We used ELISA to assess expression levels of VEGF in hypoxic cetuximab-treated MGC803 and SGC7901 cells. Cells were treated with cetuximab (50 μg/ml), oxaliplatin (100 μM, 200 μM) or a combination of both agents for 24 or 48 h under hypoxic or normoxic conditions as described above and VEGF levels were assayed. We showed that cetuximab, oxaliplatin, and different oxygen concentrations all influenced the expression of VEGF in both cell lines (Fig. 5). We showed that hypoxia resulted in a statistically significant increase in VEGF expression (p<0.001). Treatment with cetuximab alone led to an inhibition of VEGF expression in hypoxia as well as normoxia. Treatment with oxaliplatin alone also led to an inhibition of VEGF in a dose-dependent manner. Combination treatment had a synergistic effect on inhibition of VEGF expression in normoxia as well as hypoxia, although the inhibition was more pronounced in hypoxia.

Discussion

The HIF-1α pathway has impacted current treatment strategies of solid tumors such as gastric cancer since hypoxia in tumors is associated with poor prognosis and resistance to chemotherapy (14,15,36,37). Our results were in accord with previous studies (38,39) that hypoxia caused a significant upregulation in the expression level of HIF-1α with a simultaneous increase in drug resistance of gastric cancer cells. Expression levels of HIF-1α, ERK, phospho-ERK1/2, AKT, phospho-AKT, BAD, phospho-BAD and BAX were determined by Western blot analysis using appropriate antibodies. GAPDH was also blotted as protein loading control.

Figure 4. Effect of cetuximab-oxaliplatin treatment on expression levels of HIF-1α and EGFR downstream signaling targets. (a) Reduction of HIF-1α levels in cetuximab-oxaliplatin-treated MGC803 cells. (b) Inhibition of MAPK phosphorylation in cetuximab-oxaliplatin-treated MGC803 cells. (c) Effect of cetuximab and oxaliplatin on phosphorylation of AKT downstream targets and on the expression of BAX under normoxic and hypoxic conditions. MGC803 cell were left untreated or treated with cetuximab (50 μg/ml), oxaliplatin (100 μM, 200 μM) or the combination for 24 h. Expression levels of HIF-1α, ERK, phospho-ERK1/2, Akt, phospho-AKT, BAD, phospho-BAD and BAX were determined by Western blot analysis using appropriate antibodies. GAPDH was also blotted as protein loading control.
showing that blockade of EGFR pathways by cetuximab inhibited the expression of HIF-1α in hypoxia (25,29,41-45). We showed that cetuximab-mediated down-regulation of ERK1/2 and AKT phosphorylation, especially in hypoxic gastric cancer cells, led to the downstream inhibition of HIF-1α. Although our results are not direct evidence, they suggest that cetuximab-oxaliplatin treatment results in decreased expression of HIF-1α which leads to enhanced apoptosis of hypoxic gastric cancer cells. We plan to use siRNA-mediated HIF-1α silencing or generate HIF-1α null cell lines in order to further support our conclusion.

Oxaliplatin-cetuximab combination therapy resulted in more significantly cytotoxic effects in hypoxic gastric cancer cells than in normoxic cells. We showed that hypoxia protected gastric cancer cells from oxaliplatin-induced apoptosis. Treatment of hypoxic cells with a cetuximab-oxaliplatin combination treatment resulted in more intense induction of apoptosis when compared with normoxic cells.

Recent studies showed that blocking EGFR and the downstream MAPK and PI3-K activity led to a decrease in Ser112 phosphorylation of BAD and subsequent induction of apoptosis (36). Our data showed that decreased AKT and ERK1/2 phosphorylation and decreased Ser112 phosphorylation of BAD (Fig. 4c) were associated with enhanced oxaliplatin-cetuximab induced apoptosis. Our data indicated that phospho-BAD levels decreased more significantly in oxaliplatin-cetuximab treated hypoxic cells, than in oxaliplatin-cetuximab treated normoxic cells. pBAD is known to associate with 14-3-3 leading to cell survival and is down-regulated in a HIF-1α-independent manner in several different hypoxic cell lines (46). Inhibition of BAD phosphorylation leads to a physical association of BAD with Bcl-xl and results in increased apoptosis (34,35). We propose that oxaliplatin-cetuximab combination therapy acts via inhibition of BAD phosphorylation in order to promote apoptosis in hypoxic cells. Our results were in accord with previous studies (11,46) that the inhibitory effect exerted by cetuximab on BAD phosphorylation was more significant in hypoxia than in normoxia. In summary, our results lead us to speculate that cetuximab enhances oxaliplatin-mediated apoptosis by reducing HIF-1α expression and p-BAD levels via inhibition MAPK and PI3-K/AKT signaling downstream of EGFR.

Angiogenesis in hypoxia is a critical step in the pathogenesis of most cancers. VEGF has been identified as one of the key growth factors mediating this process and is a primary transcriptional target of HIF-1 (6-8). There is growing evidence (27,47-49) that growth factors and hypoxia act by enhancing the translation and stability of HIF-1α via activation of MAPK or PI3K/AKT pathways which in turn regulate VEGF expression. Our data showed that cetuximab-mediated inhibition of AKT and ERK1/2 phosphorylation resulted in decreased HIF-1α expression and a subsequent inhibition of
VEGF expression. Combination treatment with cetuximab and oxaliplatin resulted in an even greater inhibition of hypoxia-induced expression of VEGF than oxaliplatin treatment alone. Our data are in agreement with previous studies that inhibition of EGFR by monoclonal antibodies led to reduced expression of VEGF and inhibition of angiogenesis (7,8,24,27,49). It is important to investigate if VEGF inhibition by cetuximab-oxaliplatin combination therapy in our system translates to a similar synergistic effect in clinical situations.

Cetuximab was recently used in a clinical trial in combination with a modified version of FOLFIRI6 to treat gastric cancer (50). Not surprisingly, this study showed that patients with EGFR expression and low levels of competitive ligands (EGF and TGFα) had a 100% response rate. Biomarkers such as these, which can be used to optimize treatment strategies make molecules like cetuximab especially attractive in the treatment of aggressive diseases such as gastric cancer.

In conclusion, we showed that cetuximab played an important role in overcoming hypoxia-mediated drug resistance in gastric cancer cell lines. We propose a novel mechanism whereby cetuximab-oxaliplatin combination therapy results in a reduction of HIF-1α protein synthesis via MAPK/ERK and PI3-K/AKT pathways leading to a subsequent inhibition of VEGF expression. To our knowledge, we are the first to demonstrate potentiation of oxaliplatin by cetuximab via inhibition of BAD phosphorylation leading to increased apoptosis in hypoxic gastric cancer cells. Our findings also provide a molecular basis in using oxaliplatin-cetuximab combination treatment to improve clinical outcomes in gastric cancer. Our future goals include establishing xenografts of gastric cancer cells to assess the efficacy of the cetuximab-oxaliplatin combination in vitro.

Acknowledgements

This study was supported by National Natural Science Foundation of China grant 30672408, Guangzhou Bureau of Science and Technology grant 2006GZ-0041 and Sun Yat-sen University 985 Program Initiation Fund (China).

References


